Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials

Daogen Yin, MSa, Mei Qiu, MSa, Xubin Wei, MSb, Xueyan Duan, BSA,*

Abstract

Background: The factors affecting the efficacy of gliflozins in patients with heart failure (HF) are not clear. We aimed to evaluate the effects of 11 important factors on the efficacy of gliflozins in HF patients.

Methods: Randomized trials assessing gliflozins in HF patients were included. The outcome of interest was composite HF outcome, a composite of cardiovascular death, or hospitalization for HF. Meta-analysis was done according to 11 factors: status of type 2 diabetes, sex, use of angiotensin receptor-neprilysin inhibitor, age, history of hospitalization for HF, estimated glomerular filtration rate, body mass index, New York Heart Association (NYHA) class, race, region, and left ventricular ejection fraction.

Results: Compared with placebo, gliflozins reduced the risk of composite HF outcome by 14% in the subgroup of patients with NYHA class III or IV (hazard ratios [HR] 0.86, 95% confidence intervals [CI] 0.75–0.99), by 34% in the subgroup of patients with NYHA class II (HR 0.66, 95% CI 0.59–0.74), and by 85% in the subgroup of patients with NYHA class I (HR 0.15, 95% CI 0.03–0.73). This between-group difference was approximate to statistical significance (P sub group = .06). The benefit of gliflozins in HF patients was not affected by the other 10 factors (P sub group ≥ .123).

Conclusions: Gliflozins are applicable for a broad population of HF patients as for preventing HF events, while gliflozins may lead to greater benefits in patients with mild HF than in those with moderate to severe HF.

Abbreviations: ARNI = angiotensin receptor-neprilysin inhibitor, BMI = body mass index, CIs = confidence intervals, CV = cardiovascular, eGFR = estimated glomerular filtration rate, HF = heart failure, HHF = hospitalization for heart failure, HRs = hazard ratios, LVEF = left ventricular ejection fraction, NYHA = New York Heart Association, RCTs = randomized controlled trials, SGLT2is = sodium-glucose transporter 2 inhibitors.

Keywords: gliflozins, heart failure, SGLT2is

1. Introduction

Heart failure (HF) is an increasing and major public health concern worldwide.[1-3] Despite current advances in the treatment of HF, HF remains a highly prevalent disease with substantial morbidity and mortality.[4,5] Recently, a novel drug class of sodium-glucose transporter 2 inhibitors (SGLT2is) has garnered considerable attention in terms of treating HF.[3,6,1] Large randomized trials[7-9] of patients with HF have revealed the evident efficacy of SGLT2is in lowering HF-associated events among HF patients. However, individual trials do not have sufficient statistical power to evaluate HF-associated endpoints with SGLT2is in various subgroups of HF patients with different baseline characteristics.

A prior meta-analysis[10] which included 2 HF trials[7,8] identified that 7 factors related to baseline characteristics of patients, namely, status of type 2 diabetes, sex, use of angiotensin receptor-neprilysin inhibitor (ARNI), age, history of hospitalization for HF (HHF), estimated glomerular filtration rate (eGFR), and body mass index (BMI), did not significantly affect the efficacy of SGLT2is in HF patients; whereas 3 factors, namely, New York Heart Association (NYHA) class, race, and region, had significant effects on that of SGLT2is. However, that meta-analysis[10] failed to include the latest HF trial, namely the SOLIIST-WHF trial[9], and also failed to evaluate the impact of left ventricular ejection fraction (LVEF) on the effects of gliflozins in HF patients. Thus, we aimed to carry out an updated meta-analysis including all available HF trials of gliflozins, to evaluate whether 11 factors including 10 factors evaluated in Zannad meta-analysis[10] and...
LVEF significantly influence the efficacy of gliflozins in HF patients.

2. Methods
We conducted this study of meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.\[11]\]

2.1. Search strategy and inclusion criteria
Embase and PubMed were searched using the pre-planned retrieval strategy (see Table S1, Supplemental Digital Content, http://links.lww.com/MD/G265, which illustrates the whole search strategy respectively used in Embase and PubMed). We searched the databases from the creation date of databases to May 1, 2021. The included studies in this meta-analysis were randomized controlled trials (RCTs) which only enrolled HF patients and compared any SGLT2i with placebo in terms of preventing composite HF outcome. The composite HF outcome was defined as a composite of cardiovascular (CV) death or HHF (preferred), or a composite of CV death or hospitalization or an urgent visit for HF (second choice). The conference articles and grey articles were not considered in this meta-analysis.

2.2. Study selection, data extraction, and quality assessment
After literature retrieval, 2 authors independently implemented study selection, followed by data extraction. The pre-planned data to be extracted from included studies contained study type, type of active treatments, type of comparators, and study outcomes from pre-defined subgroups. Subgroups of interest were respectively defined by the following 11 factors: status of type 2 diabetes (with or without type 2 diabetes), sex (men or women), use of ARNI (yes or no), age (\(\leq 65\) years or \(>65\) years), history of HHF (yes or no), eGFR (\(<60\) mL/min per 1.73 m\(^2\) or \(\geq 60\) mL/min per 1.73 m\(^2\)), NYHA class (Class III or IV, Class II, or Class I), race (White, Black, or Asian), region (North America, Latin America, Europe, or Asia), BMI (\(<30\) kg/m\(^2\) or \(\geq 30\) kg/m\(^2\)), and LVEF (\(<40\%\) or \(\geq 40\%\)). Included RCTs were evaluated for risk of bias independently by 2 authors, according to the Cochrane risk of bias assessment tool.\[12]\] Any disagreements between the 2 authors mentioned above would be discussed with a third author until an agreement was reached.

2.3. Statistical analysis
We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) from included articles, to conduct a meta-analysis using the random-effects inverse-variance model. Statistical heterogeneity was evaluated by \(I^2\) statistic, and this value greater than 50% represents substantial heterogeneity. Subgroup analysis was performed, respectively stratified by the 11 factors of interest. Random-effects meta-regression analysis was done to examine subgroup effects. \(P_{\text{subgroup}} < .05\) is considered as statistical significance. All data analyses regarding this meta-analysis were conducted in the Stata/MP software (version 16.0).

![Figure 1](https://example.com/image1.png)

**Figure 1.** Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by NYHA class. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles, NYHA = New York Heart Association. “X” and “−X” indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, “X” and “810−X” means that the total number of patients in 2 subgroups was 810.
Figure 2. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by status of type 2 diabetes. CI = confidence interval, HR = hazard ratio.

Figure 3. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by sex. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles. "X" and "–X," indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, "X" and "810 – X" means that the total number of patients in 2 subgroups was 810.
**Figure 4.** Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by use of ARNI. ARNI = angiotensin receptor-neprilysin inhibitor. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles. “X” and “−X,” indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, “X” and “810 − X” means that the total number of patients in 2 subgroups was 810.

**Figure 5.** Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by age. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles. “X” and “−X,” indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, “X” and “810 − X” means that the total number of patients in 2 subgroups was 810.
Figure 6. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by history of HHF. CI = confidence interval, HHF = hospitalization for heart failure, HR = hazard ratio.

Figure 7. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by eGFR. CI = confidence interval, eGFR = estimated glomerular filtration rate, HR = hazard ratio, NR = not reported in included articles. “X” and “−X” indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, “X” and “810−X” means that the total number of patients in 2 subgroups was 810.
Figure 8. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by race. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles. "X" and "~X," indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, "X" and "810 ~X" means that the total number of patients in 2 subgroups was 810.

Figure 9. Impact of gliflozins on composite heart failure outcome in heart failure patients, stratified by region. CI = confidence interval, HR = hazard ratio, NR = not reported in included articles. "X" and "~X," indicate that the number of patients in each subgroup was not reported in included articles, but the total number of patients in 2 subgroups was available. For instance, "X" and "810 ~X" means that the total number of patients in 2 subgroups was 810.
2.4. Ethical statement

The data analyzed in this study were extracted from previously published studies, and thus ethical approval was not necessary.

3. Results

3.1. Characteristics of included trials

The process of study selection is detailed in Figure S1, Supplemental Digital Content, http://links.lww.com/MD/G263, which illustrates the whole study selection process. Finally, we included 3 RCTs only enrolling HF patients: DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials enrolling HF patients regardless of with/without type 2 diabetes and SOLOIST-WHF (assessing sotagliflozin) trial enrolling patients with HF and concomitant type 2 diabetes. The included 3 trials involved 9696 HF patients in total. The mean age across included trials ranged from 66.3 to 70.0 years, and the median duration of follow-up ranged from 0.8 to 1.5 years. The risk of bias of included trials was low, as is presented in Figure S2, Supplemental Digital Content, http://links.lww.com/MD/G264, which summarizes the risk of bias of included trials. The original data extracted from included studies are provided in Table S2, Supplemental Digital Content, http://links.lww.com/MD/G266, which illustrates the whole data extracted from included articles.

3.2. Meta-analyses

Figure 1 presents the results of the meta-analysis of the impact of gli flozins on composite HF outcome in 3 subgroups with different NYHA classes. Compared with placebo, gli flozins significantly reduced the risk of composite HF outcome in the subgroup of patients with NYHA class III or IV (HR 0.86, 95% CI 0.75–0.99; P for effect size = 0.032; I² = 0), in the subgroup of patients with NYHA class II (HR 0.66, 95% CI 0.59–0.74; P for effect size < 0.001; I² = 0), and in the subgroup of patients with NYHA class I (HR 0.15, 95% CI 0.03–0.73; P for effect size = 0.019; I² = 0). Gli flozins vs placebo reduced composite HF outcome by 14% in the NYHA class III or IV subgroup, by 34% in the NYHA class II subgroup, and by 85% in the NYHA class I subgroup; and this between-group difference was approximate to statistical significance (P subgroup = 0.06). Compared with placebo, gli flozins significantly reduced composite HF outcome (HR 0.73, 95% CI 0.67–0.80; P for effect size < 0.001), independent of the following 10 factors: status of type 2 diabetes (P subgroup = 0.673, Fig. 2), sex (P subgroup = 0.699, Fig. 3), use of ARNI (P subgroup = 0.987, Fig. 4), age (P subgroup = 0.749, Fig. 5), history of HHF (P subgroup = 0.439, Fig. 6), eGFR (P subgroup = 0.965, Fig. 7), race (P subgroup = 0.324, Fig. 8), region (P subgroup = 0.123, Fig. 9), BMI (P subgroup = 0.915, Fig. 10), and LVEF (P subgroup = 0.737, Fig. 11).

4. Discussion

This meta-analysis evaluated the impact of 11 important factors (ie, NYHA class, status of type 2 diabetes, sex, use of ARNI, age, history of HHF, eGFR, race, region, BMI, and LVEF) on the efficacy of gli flozins in HF patients. Therefore, it identified that 10 factors (ie, status of type 2 diabetes, sex, use of ARNI, age, history of HHF, eGFR, race, region, BMI, and LVEF) did not significantly affect the efficacy of gli flozins in HF patients (P subgroup ≥ 0.123), whereas NYHA class affected the efficacy of
glioflozins in HF patients with approximate statistical significance ($P_{\text{subgroup}} = .06$). To be more specific, glioflozins led to a greater reduction in composite HF outcome among patients with NYHA class I (vs placebo: an 85% reduction) and among patients with NYHA class II (vs placebo: a 34% reduction) than among patients with NYHA class III or IV (vs placebo: a 14% reduction).

An initial meta-analysis based on 2 HF trials of glioflozins suggested the consistent benefits of this drug class for the subgroups based on baseline eGFR, use of ARNI, diabetes, sex, and age, but suggested the treatment-by-subgroup interactions for the subgroups based on race and NYHA class. The present meta-analysis additionally included the latest HF trial of glioflozins, the SOLOIST-WHF trial assessing sotagliflozin, and accordingly provided the up-to-date evidence regarding the factors affecting the efficacy of glioflozins in HF patients.

Several meta-analyses confirmed the benefits of glioflozins on CV and renal outcomes in HF patients, and moreover, some of them also revealed that these benefits of glioflozins in HF patients were independent of diabetes status, LVEF, and use of ARNI. However, the previous meta-analyses failed to evaluate the impact of most of the factors assessed in the present meta-analysis on the efficacy of glioflozins. Thus, the findings of this meta-analysis will further inform cardiologists and HF patients that glioflozins are applicable for a broad population of HF patients as for preventing HF events, while glioflozins may lead to greater benefits in patients with mild HF than in those with moderate to severe HF.

Two strengths of this study were that the risk of bias of included trials in this meta-analysis was low and that no heterogeneity or only mild heterogeneity was found in most subgroups based on the factors of interest. Oppositely, this study has the following limitations. First, moderate to severe heterogeneity was found in a few subgroups of interest, which needs to be clarified by future meta-analyses of individual patient data. Second, we did not perform the detection of publication bias due to the limited number of included trials. Therefore, we failed to grade the quality of evidence with the Grading of Recommendations Assessment, Development, and Evaluation statement because in this statement several points including the result of publication bias should be considered. Last, the mechanism by which glioflozins lead to greater benefits in patients with mild HF than in those with moderate to severe HF requires to be further investigated.

In conclusion, glioflozins are applicable for a broad population of HF patients as for preventing HF events, while glioflozins may lead to greater benefits in patients with mild HF than in those with moderate to severe HF.

Author contributions
Conceptualization: Xueyan Duan.
Data curation: Daogen Yin, Mei Qiu, Xubin Wei.
Formal analysis: Daogen Yin.
Writing – original draft: Daogen Yin, Mei Qiu.
Writing – review & editing: Xubin Wei, Xueyan Duan.
References

[1] Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368–78.
[2] Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017;70:2476–86.
[3] Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014;168:721–30.
[4] Braunwald E. The war against heart failure: the Lancet lecture. Lancet 2015;385:812–24.
[5] Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail 2019;6:1105–27.
[6] Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1023–9.
[7] McMurray J, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.
[8] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24.
[9] Bhatt DL, Szarek M, Steg PG, et al. Sotagliblozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117–28.
[10] Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet 2020;396:819–29.
[11] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[12] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[13] Li X, Zhang Q, Zhu L, et al. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2021;332:119–26.
[14] Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: a meta-analysis of randomized controlled trials. Eur J Intern Med 2021.
[15] Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail 2020;7:3298–309.
[16] Patoulas D, Papadopoulos C, Kalogirou MS, Katsimardou A, Toupourleka M, Doumas M. Updated meta-analysis assessing the effect of sodium-glucose co-transporter-2 inhibitors on surrogate end points in patients with heart failure with reduced ejection fraction. Am J Cardiol 2020;137:130–2.
[17] Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol 2021;20:83.
[18] Camilli M, Lombardi M, Chiabrando JG, et al. Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021.
[19] Yan Y, Liu B, Du J, et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 2021.
[20] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.